578 results on '"Zinman, Bernard"'
Search Results
2. Postpartum weight retention and the early evolution of cardiovascular risk over the first 5 years after pregnancy
3. Effect of qualifying atherosclerotic cardiovascular disease diagnosis proximity on cardiovascular risk and benefit of empagliflozin in EMPA-REG OUTCOME
4. Future cardiometabolic implications of insulin hypersecretion in response to oral glucose: a prospective cohort study
5. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
6. Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk
7. Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome
8. Deteriorating beta cell function is the dominant determinant of progression from normal glucose tolerance to prediabetes/diabetes in young women following pregnancy
9. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
10. Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes
11. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
12. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
13. Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial
14. Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes
15. Treatment of Gestational Diabetes Mellitus and Maternal Risk of Diabetes After Pregnancy
16. Treatment of Gestational Diabetes and Maternal Risk of Diabetes after Pregnancy
17. Treatment of Gestational Diabetes and Maternal Risk of Diabetes after Pregnancy
18. Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445–2448
19. Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
20. Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
21. Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
22. Insulin-sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8
23. RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
24. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial
25. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
26. Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?
27. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
28. Determinants of Small for Gestational Age in Women with Type 2 Diabetes in Pregnancy: Who should get Metformin?
29. Determinants of Small for Gestational Age in Women with Type 2 Diabetes in Pregnancy: Who should get Metformin?
30. 249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status
31. 248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial
32. 721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8
33. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
34. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial
35. Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
36. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
37. Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life
38. Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life
39. Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life
40. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
41. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
42. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
43. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
44. Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
45. Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
46. Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
47. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes
48. Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
49. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
50. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.